Ebola: Why Do Some Patients Survive While Others Succumb to the Disease?

By Ana Espino | Published on June 01, 2026 | 4 min read

Ebola virus disease remains one of the deadliest infections in the world. Despite significant advances in supportive care and the recent introduction of targeted therapies such as monoclonal antibodies, its mortality rate remains high and varies considerably from one outbreak to another. This variability can be partly explained by differences in healthcare systems, access to specialized treatments, and patient characteristics.

Although several clinical factors have already been associated with an increased risk of death—such as older age, high viral load, or severe disease manifestations—the available evidence remains fragmented. Published studies often differ in methodology, sample size, and outcome measures, making it difficult to identify true prognostic factors.

To better understand which elements genuinely influence disease outcomes, a team of researchers conducted a systematic review and meta-analysis of the available data on Ebola-related mortality. Their objective was to estimate the overall case fatality rate of the disease and identify the main clinical factors associated with death.

Uncovering the Factors That Determine Disease Outcome

The researchers analyzed data from 11 studies conducted between 2013 and 2020, involving more than 16,000 patients with Ebola virus disease across West and Central Africa.

Using a random-effects meta-analysis, they assessed overall mortality as well as the impact of various clinical parameters on the risk of death. The analyses also accounted for differences in epidemic settings, age groups, and sample sizes.

The results showed that, on average, more than one out of every two patients infected with Ebola died from the disease. However, a notable improvement was observed during more recent outbreaks in Central Africa, where mortality rates were lower than those reported during the large West African epidemic of 2014–2016.

Among the factors examined, hemorrhagic manifestations emerged as the strongest marker of poor prognosis. Patients experiencing bleeding had a significantly higher risk of death than those without hemorrhagic symptoms. In contrast, age alone did not appear to be an independent predictor of mortality when the data were pooled.

The authors also emphasized that the differences observed across studies likely reflect the importance of factors such as rapid access to care, quality of clinical management, and availability of specialized treatments.

Could Early Access to Care Be the Key?

This study confirms that Ebola virus disease remains associated with exceptionally high mortality. It also highlights the persistent challenges faced by healthcare systems during outbreaks, including early diagnosis, rapid referral to specialized treatment centers, and access to the most effective therapies.

By identifying hemorrhagic manifestations as a major warning sign, these findings may help healthcare teams more quickly recognize high-risk patients and intensify their medical management.

However, the authors acknowledge several limitations, including substantial heterogeneity among the studies analyzed, the predominance of observational data, and the lack of standardized information on certain prognostic factors such as viral load and comorbidities.

In the future, better-harmonized studies may help refine the identification of the most vulnerable patients and optimize therapeutic strategies. Combined with ongoing improvements in clinical care and broader access to innovative treatments, these advances could contribute to further reducing Ebola-related mortality.




About the author – Ana Espino
PhD in Immunology, specialized in Virology  
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions.